Current Report Filing (8-k)
June 26 2017 - 04:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 20, 2017
Ra Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
DELAWARE
|
|
001-37926
|
|
26-2908274
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
87 Cambridge Park Drive
Cambridge, MA
|
|
02140
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(617) 401-4060
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
x
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 5.07.
Submission of Matters to a Vote of Security Holders.
(a)
On June 20, 2017, Ra Pharmaceuticals, Inc. (the
Company
) held its 2017 Annual Meeting of Stockholders (the
Annual Meeting
) at 10:00 a.m. Eastern Time at the offices of Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210. Proxies for the Annual Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended.
(b)
The following matters, which are described in detail in the Companys definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2017, were voted upon at the Annual Meeting with the number of votes cast in respect thereof as set forth below:
1.
Election of each of Douglas A. Treco, Ph.D. and Edward T. Mathers to serve as a Class I Director of the Company for a three-year term, expiring at the 2020 annual meeting of stockholders and until their respective successors are duly elected and qualified, subject to their earlier resignation or removal.
Douglas A. Treco, Ph.D.
Votes
:
For:
|
|
14,989,297
|
Withheld:
|
|
408,816
|
Broker Non-Votes:
|
|
642,428
|
Edward T. Mathers
Votes
:
For:
|
|
14,162,090
|
Withheld:
|
|
1,236,023
|
Broker Non-Votes:
|
|
642,428
|
Accordingly, each of the foregoing nominees was elected to serve as a Class I Director of the Company.
2.
Ratification of the appointment of Deloitte & Touche LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017.
Votes
:
For:
|
|
16,003,070
|
Against:
|
|
36,386
|
Abstained:
|
|
1,085
|
Accordingly, the appointment of the Companys independent registered public accounting firm was ratified.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 26, 2017
|
RA PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ David C. Lubner
|
|
|
David C. Lubner
|
|
|
Executive Vice President and Chief Financial Officer
|
3
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Mar 2023 to Mar 2024